PSF | Jotup

The Pershing Square Sohn Cancer Research Alliance Is Now Accepting Applications for its 2022 Prize for Early-Career, Radically Innovative Cancer Researchers

Retrieved on:

星期一, 十月 4, 2021

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Molecular biophysics, Partnership, Yale School of Medicine, Letter, Friends, Presidential Young Investigator Award, Pancreatic cancer, Physiology, Memory, Health, Conference, Biophysics, DNA, Cancer, Engineering, MD, Cell biology, PSF, Biochemistry, Immunotherapy, Social justice, Growth, Family, Entrepreneurship, Associate, MD–PhD, Sohn Conference Foundation, Science, Intention, Alliance, Research, Lymphatic system, Cell, Education, Economic development, Foundation, Laboratory, Memorial Sloan Kettering Cancer Center, Yale school, Weill Cornell Medicine, Wall Street, Doctor of Philosophy, Cell cycle, Industry, Pharmaceutical industry, the Pershing Square Sohn Cancer Research Alliance, The Pershing Square Foundation, The Sohn Conference Foundation, THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE, THE PERSHING SQUARE FOUNDATION, THE SOHN CONFERENCE FOUNDATION

The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for the 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research.

Key Points:

The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for the 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research.
The prize empowers researchers to pursue novel, high-risk/high-reward cancer research at a stage when traditional funding is lacking.
The Pershing Square Sohn Cancer Research Alliance was formed in 2013 by The Pershing Square Foundation, which has since committed more than $30 million to 52 scientists, in partnership with The Sohn Conference Foundation.
Annually, the Alliance awards the Pershing Square Sohn Prize to early-career, New York area scientists who are engaged in cutting-edge cancer research.

Plastic and Reconstructive Surgery Journal Achieves New High for Impact Factor Score

Retrieved on:

星期二, 九月 14, 2021

DALLAS, Sept. 14, 2021 /PRNewswire-PRWeb/ -- Plastic and Reconstructive Surgery (PRS) has recently been ranked as the most frequently cited medical journal in the discipline of plastic surgery, achieving a new record high Impact Factor score measuring the journal's influence among scientific publications.

Key Points:

DALLAS, Sept. 14, 2021 /PRNewswire-PRWeb/ -- Plastic and Reconstructive Surgery (PRS) has recently been ranked as the most frequently cited medical journal in the discipline of plastic surgery, achieving a new record high Impact Factor score measuring the journal's influence among scientific publications.
For 2021, PRS has an impact factor score of 4.730, a substantial increase from its 2020 score of 4.209.
He is the Editor-in-Chief of the most respected global peer reviewed plastic surgery journal the Plastic and Reconstructive Surgery Journal.
In addition, he has also been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations.

Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Complete Settlement of All Disputes

Retrieved on:

星期一, 三月 9, 2020

PSF, Corduliidae

VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement (the "Settlement Agreement") among Emerald, Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF" and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties have been completed.

Key Points:

VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement (the "Settlement Agreement") among Emerald, Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF" and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties have been completed.
Emerald also has no further obligations under the previously disclosed Delta 2 Option Agreement in regard to the construction of PSF's Delta 2 facility.
Emerald now holds a 42.6% equity interest in PSF and retains three of six seats on the PSF board of directors.
Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with recreational and wellness-oriented cannabis products.

Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Settle All Disputes

Retrieved on:

星期二, 三月 3, 2020

PSF

VANCOUVER, British Columbia, March 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the "Settlement Agreement") with Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF," and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties (the "Settlement").

Key Points:

VANCOUVER, British Columbia, March 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the "Settlement Agreement") with Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF," and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties (the "Settlement").
"The Settlement Agreement allows Emerald, PSF and Village Farms to put their previous disputes aside and work together toward building on the tremendous performance of PSF to date.
Emerald has also agreed to transfer 2.5% of its PSF equity to Village Farms.
The Parties have agreed that $8,000,000 provided by Village Farms to PSF in 2020 will be converted into additional common shares of PSF.

Emerald Health Therapeutics Responds to Inaccurate Allegations by Village Farms

Retrieved on:

星期三, 十一月 20, 2019

PSF

VANCOUVER, British Columbia, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) today responded to inaccurate allegations made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) in connection with their 50/50 joint venture, Pure Sunfarms Corp. ("PSF"), and updated the market on certain related matters.

Key Points:

VANCOUVER, British Columbia, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) today responded to inaccurate allegations made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) in connection with their 50/50 joint venture, Pure Sunfarms Corp. ("PSF"), and updated the market on certain related matters.
Late yesterday evening Emerald received notice from Village Farms stating that Village Farms had advanced $5.94 million to PSF for additional equity.
Despite Village Farms claims, Emerald continues to hold a full 50% ownership interest in PSF.
In connection with the exercise of PSF's option to acquire the Delta 2 facility from Village Farms, an option agreement (the "Delta 2 Option Agreement") was entered into among Emerald, Village Farms and PSF.